Crystalloid Fluid Choice and Neurological Outcome in Patients After Subarachnoid Haemorrhage

Launched by INSEL GRUPPE AG, UNIVERSITY HOSPITAL BERN · Jul 31, 2019

Keywords

ClinConnect Summary

This clinical trial is looking at how different types of intravenous (IV) fluids, specifically their sodium content, can affect the health of patients who have suffered from a subarachnoid hemorrhage (a type of brain bleed). People with this condition often develop problems with sodium levels in their blood, which can lead to serious complications like brain swelling and increased risk of death. The study aims to find out if using certain types of IV fluids can help improve the chances of recovery and reduce complications in these patients.

To participate in this trial, potential candidates must be adults who have had a non-traumatic subarachnoid hemorrhage. However, those with severe trauma to the brain, certain types of blood vessel malformations, or who are too far along in their treatment (over 24 hours after diagnosis) are not eligible. Participants can expect to receive different types of IV fluids while being closely monitored for their health outcomes. This research is important as it may help doctors make better choices about the fluids used to treat patients with this serious condition, ultimately improving recovery and survival rates.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All adult patients suffering from non-traumatic subarachnoid haemorrhage.
• Exclusion Criteria:
• • Patients with major intra-cranial trauma
• • Diagnosis of an AV-malformation as the source of subarachnoid hemorrhage on the primary CT/MRI or angiography
• • More than 24 hours after diagnosis of subarachnoid haemorrhage as diagnosed by cerebral imaging (CT scan or MRI)
• • Patients with clear limitation to therapy at hospital admission (eg ICU admission for evaluation of organ donation)
• • Declining of informed consent